{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9","upperLimit":"560","value":"72"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"240","value":"1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"title":"2 weeks"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"2147","value":"204"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"430","value":"6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"37"}],"units":"Participants"}],"title":"1 month"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"1054","value":"334"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"846","value":"54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"3 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79","upperLimit":"1487","value":"429"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"1302","value":"158"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64","upperLimit":"1844","value":"485"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"2861","value":"243"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"121","upperLimit":"1928","value":"434"},{"groupId":"OG001","lowerLimit":"92","upperLimit":"4239","value":"502"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Cluster of differentiation 3 (CD3)+cluster of differentiation 4 (CD4)+ and CD3+CD8+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.","dispersionType":"Full Range","groups":[{"description":"TMS Arm Rituximab: 375 mg/m2 IV, day 1 for patients with cluster of differentiation 20 (CD20)-positive disease Allogenic stem cell transplant (ASCT):Allogenic stem cell transplant Conditioning Chemotherapy:Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna:1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 TMS: Tacrolimus: 0.02 mg/kg, start day 3. Continue IV or PO. Taper will begin at day +63 if no acute GVHD then at day +119 and discontinue at day +180 as tolerated Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11 Sirolimus: 12 mg PO on days -3 to 63, followed by a taper if GVHD does not develop.\n\nFLAG: Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours, on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy","id":"OG000","title":"A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm"},{"description":"Rituximab375 mg/m2 IV, day 1 for pts with CD20-positive disease. Cyclosporine IV over 2 hrs or orally every 12 hrs on days -1-100, followed by a taper if GVHD does not develop. Allogenic stem cell transplant. Conditioning Chemotherapy Fludarabine:30 mg/m2 per day IV infusion over 30 min., daily on days -6, -5, -4, and -3. Cyclophosphamide1200 mg/m2 per day IV infusion over 2 hrs on Days 6, -5, -4, -3. Mesna1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3. FLAG: Fludarabine25 mg/m2 per day IV over 30 min., Daily on days 1-5. Cytarabine 2,000 mg/m2 IV over 4 hrs, on Days 1, 2, 3, 4, 5. Filgrastim 5 mcg/kg per day SC beginning 24 hrs PRIOR to start of chemotherapy. EPOCH-F: Fludarabine25 mg/m2 per day IV infusion over 30 min., daily on days 1-4. Etoposide 50 mg/m2 per day continuous IV infusion over 24 hrs on days 1-4. Doxorubicin10 mg/m2/d. Grp 2 Alemtuzumab for 4 days starting 8 days before SCT + cyclosporine starting 1 day before SCT and continuing for 6 months.","id":"OG001","title":"B - Cyclosporine (AC) Arm"}],"paramType":"MEDIAN","populationDescription":"2 of 44 patients who completed the AC arm were transplanted after our cutoff for data analysis and are not included. A total of 5 completed participants did not contribute data due to missing samples, and participants who died and were not able to supply samples for the time points indicated.","reportingStatus":"POSTED","timeFrame":"2 weeks, 1, 3, 6, 12 and 24 months post transplant","title":"Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations","type":"SECONDARY","unitOfMeasure":"Cells/µl"}